SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:liu-86994"
 

Sökning: id:"swepub:oai:DiVA.org:liu-86994" > Targeting the EGFR ...

Targeting the EGFR pathway for cancer therapy

Johnston, James B. (författare)
University of Manitoba,Winnipeg, MB,R3E 0V9, Canada
Navaratnam, Sri (författare)
University of Manitoba,Winnipeg, MB,R3E 0V9, Canada
Pitz, Marshall W. (författare)
University of Manitoba,Winnipeg, MB,R3E 0V9, Canada
visa fler...
Maniate, Jerry M. (författare)
University of Manitoba,Winnipeg, MB,R3E 0V9, Canada
Wiechec, Emilia (författare)
Manitoba Institute of Cell Biology, CancerCare Manitoba
Baust, Heinrich (författare)
University of Manitoba,Winnipeg, MB,R3E 0V9, Canada
Gingerich, Joel (författare)
University of Manitoba,Winnipeg, MB,R3E 0V9, Canada
Skliris, Georgios P. (författare)
University of Manitoba,Winnipeg, MB,R3E 0V9, Canada
Murphy, Leigh C. (författare)
University of Manitoba,Winnipeg, MB,R3E 0V9, Canada
Los, Marek Jan (författare)
Manitoba Institute of Cell Biology, Cancer Care Manitoba; Manitoba Institute of Child Health; Department of Biochemistry and Medical Genetics; Department of Human Anatomy and Cell Science, University Manitoba, Winnipeg, Canada,
visa färre...
 (creator_code:org_t)
Bentham Science Publishers Ltd. 2006
2006
Engelska.
Ingår i: Current Medicinal Chemistry. - : Bentham Science Publishers Ltd.. - 0929-8673 .- 1875-533X. ; 13:29, s. 3483-3492
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Clinical studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resistant to conventional chemo-therapies. Additionally, in most patients with multiple myeloma, the malignant cells over-express a number of epidermal growth factor receptors (EGFR)s and their ligands, HB-EGF and amphiregulin, thus this growth-factor family may be an important aspect in the patho-biology of this disease. These and other, related findings have provided the rationale for the targeting of the components of the EGFR signaling pathways for cancer therapy. Below we discuss various aspects of EGFR-targeted therapies mainly in hematologic malignancies, lung cancer and breast cancer. Beside novel therapeutic approaches, we also discuss specific side effects associated with the therapeutic inhibition of components of the EGFR-pathways. Alongside small inhibitors, such as Lapatinib (Tykerb, GW572016), Gefitinib (Iressa, Z131839), and Erlotinib (Tarceva, OSI-774), a significant part of the review is also dedicated to therapeutic antibodies (e.g.: Trastuzumab / Herceptin, Pertuzumab / Omnitarg / rhuMab-2C4, Cetuximab / Erbitux / IMC-C225, Panitumumab / Abenix / ABX-EGF, and also ZD6474). In addition, we summarize, both current therapy development driven by antibody-based targeting of the EGFR-dependent signaling pathways, and furthermore, we provide a background on the history and the development of therapeutic antibodies.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
NATURVETENSKAP  -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)

Nyckelord

acute lymphoblastic-leukemia
acute myeloid-leukemia
cancer therapy
cell lung-cancer
cetuximab
egfr
erlotinib
gefitinib
growth-factor
lapatinib
metastatic breast-cancer
monoclonal-antibody
phase-ii trial
previously treated patients
randomized-trial
receptor tyrosine kinase
trastuzumab

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy